829 related articles for article (PubMed ID: 21204103)
1. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
3. Assessing remission in clinical practice.
Mierau M; Schoels M; Gonda G; Fuchs J; Aletaha D; Smolen JS
Rheumatology (Oxford); 2007 Jun; 46(6):975-9. PubMed ID: 17341506
[TBL] [Abstract][Full Text] [Related]
4. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
[TBL] [Abstract][Full Text] [Related]
5. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
Martins FM; da Silva JA; Santos MJ; Vieira-Sousa E; Duarte C; Santos H; Costa JA; Pimentel-Santos FM; Cunha I; Cunha Miranda L; Nóvoa T; Cruz M; Bernardes M; Araujo D; Pereira Silva JA; Silva JC; Branco JC; Gomes JA; Faustino A; Fonseca JE; Canhão H
Rheumatology (Oxford); 2015 Feb; 54(2):286-91. PubMed ID: 25173347
[TBL] [Abstract][Full Text] [Related]
6. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
7. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
8. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
9. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
10. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
11. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
12. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
Kaneko Y; Kondo H; Takeuchi T
J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
[TBL] [Abstract][Full Text] [Related]
13. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
[TBL] [Abstract][Full Text] [Related]
14. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
Mack ME; Hsia E; Aletaha D
Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
Nishimoto N; Takagi N
Mod Rheumatol; 2010 Dec; 20(6):539-47. PubMed ID: 20617358
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
[TBL] [Abstract][Full Text] [Related]
17. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three rheumatoid arthritis disease activity scores in clinical routine.
Rintelen B; Sautner J; Haindl PM; Andel I; Maktari A; Leeb BF
Scand J Rheumatol; 2009; 38(5):336-41. PubMed ID: 19585379
[TBL] [Abstract][Full Text] [Related]
20. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
Futó G; Somogyi A; Szekanecz Z
Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
